EP0450660B1 - Anti-atherosclerotic diaryl compound - Google Patents
Anti-atherosclerotic diaryl compound Download PDFInfo
- Publication number
- EP0450660B1 EP0450660B1 EP91107475A EP91107475A EP0450660B1 EP 0450660 B1 EP0450660 B1 EP 0450660B1 EP 91107475 A EP91107475 A EP 91107475A EP 91107475 A EP91107475 A EP 91107475A EP 0450660 B1 EP0450660 B1 EP 0450660B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- formula
- solvate
- formulation
- physiologically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C327/44—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- the present invention is concerned with a new diaryl compound, processes for its preparation, compositions containing it and their use in medicine, particularly in the prophylaxis or treatment of atherosclerosis.
- acyl coenzyme A cholesterol acyl transferase (ACAT), cholesteryl ester hydrolase (CEH), acid cholesterol hydrolase and cholesteral esterase.
- ACAT and cholesteryl ester hydrolase appear to control the steady state concentration of cholesterol ester in the arterial wall : ACAT may also play a key role in the gastrointestinal absorption of cholesterol on the basis that (a) more than 90% of the cholesterol which appears in the lymph is esterified, (b) substantial ACAT activity has been observed in the intestinal mucosal cells of several animal species, (c) the site of greatest intestinal ACAT activity is the jejunum where the majority of cholesterol absorption occurs, (d) ACAT activity in the jejunum parallels increases in dietary cholesterol and (e) ACAT activity is significantly enhanced in animals having experimental atherosclerosis and in atherosclerotic human tissue and cell cultures.
- US Patent 4,603,145 and European Patent Application 0297610 Compounds having ACAT-inhibitory activity are known from US Patent 4,603,145 and European Patent Application 0297610.
- USP '145 describes novel diarylalkanamides useful as pharmaceutical agents for ameliorating atherosclerosis by inhibiting the formation and development of atherosclerotic lesions in the arterial wall of mammals.
- EPA '610 describes substituted urea, thiourea, carbamate and thiocarbamate derivatives which are potent inhibitors of ACAT and are thus useful agents for inhibiting the intestinal absorption of cholesterol.
- Salts of the compound of formula (I) suitable for use in medicine are those which are physiologically acceptable.
- non-physiologically acceptable salts are within the scope of the present invention for use as intermediates in the preparation of the compound of the invention and its physiologically acceptable salts and solvates.
- the ability of the compound of formula (I) to inhibit ACAT activity renders it useful as a hypolipidaemic and in reducing the steady state concentration of cholesterol and cholesterol ester in the arterial wall, thereby retarding the build-up of atherosclerotic lesions and providing application for this compound in the prophylaxis or treatment of atherosclerosis.
- a daily dose is expected to lie in the range of from 1ng to 100mg, typically from 50ng to 50mg, per day per kilogram bodyweight, for example, 500ng-5mg/kg/day.
- An intravenous dose may, for example, be in the range of from 10ng to 1 mg/kg which may conveniently be administered as an infusion of from 0.1ng to 50g per kilogram per minute.
- Infusion fluids suitable for this purpose may contain, for example, from 0.01ng to 100g, typically from 0.1ng to 100g, per millilitre.
- Unit doses may contain from 100ng to 100mg of the active compound; for example, ampoules for injection may contain from 100ng to 1mg and orally administrable unit dose formulations, such as tablets or capsules, may contain, for example, from 0.001 to 50mg, typically from 0.02 to 20mg.
- the weights indicated above refer to the weight of the diaryl ion derived from the salt.
- the compound of formula (I) may be used as the compound per se , but is preferably presented with an acceptable carrier as a pharmaceutical formulation.
- the carrier must, of course, be acceptable in the sense of being compatible with the other ingredients of the formulation and not be deleterious to the recipient thereof.
- the carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a unit dose formulation, for example, a tablet, which may contain from 0.05% to 95% by weight of the compound.
- Other pharmacologically active substances may also be present in the formulations of the present invention.
- One or more forms of the compound of formula (I) may be incorporated in the formulations of the invention, which may be prepared by any of the well known techniques of pharmacy consisting essentially of admixture of the components.
- the formulations include those suitable for oral, rectal, topical, buccal (e.g. sub-lingual) and parenteral (e.g. subcutaneous, intramuscular, intradermal, or intravenous) administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular form of the compound of formula (I) which is being used.
- Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of the compound of formula (I) or of a physiologically acceptable salt thereof; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
- Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the compound and the carrier (which may constitute one or more accessory ingredients). In general, the formulations are prepared by uniformly and intimately admixing the compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product.
- a tablet may be prepared by compressing or moulding a powder or granules of the compound, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent and/or surface-active/dispersing agent(s).
- Moulded tablets may be made by moulding, in a suitable machine, the powdered compound moistened with an inert liquid diluent.
- Formulations suitable for buccal (sub-lingual) administrations include lozenges comprising the compound of formula (I), or a physiologically acceptable salt thereof, in a flavoured base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.
- Formulations of the present invention suitable for parenteral administration conveniently comprise sterile aqueous preparations of the compound of formula (I), or of a physiologically acceptable salt thereof, which preparations are preferably isotonic with the blood of the recipient.
- the preparations are preferably administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection.
- Such preparations may conveniently be prepared by admixing the compound with water and rendering the resulting solution sterile and isotonic with the blood.
- Injectable compositions according to the invention will generally contain from 0.1 to 5% w/w of the compound of formula (I).
- Formulations suitable for rectal administration are preferably presented as unit dose suppositories. These may be prepared by admixing the compound of formula (I), or a physiologically acceptable salt thereof, with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
- Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include vaseline, lanoline, polyethylene glycols, alcohols and combinations of two or more therof.
- the active compound is generally present at a concentration of from 0.1 to 15% w/w of the composition, for example, from 0.5 to 2%.
- the compound of formula (I) may be prepared in any conventional manner, for example, by the process described below.
- the compound of formula (I) may be prepared by reacting a compound of formula (II) C7H15-P (II) wherein P is as defined below, with a compound of formula (III) wherein Q is a nucleophilic group, for example, amino, capable of reacting with the group P, for example, isocyanate, in compound (II) to give the compound of formula (I).
- the reaction is typically carried out in a non-polar solvent, such as THF, in the presence of a suitable base, for example, DMAP.
- Compounds of formula (III) may be prepared by reacting a compound of formula (IV) wherein R is a group capable of being converted to the group Q of compound (III), with a suitable reagent or reagents and under such conditions as to effect conversion of R to Q, for example, converting a nitro group to an amino group by catalytic hydrogenation.
- Compounds of formula (IV) may be prepared by selectively reducing the carbonyl group of a compound of formula (V) wherein R is as hereinbefore defined, using, for example, triethylsilane in the presence of trifluoroacetic acid.
- Compounds of formula (V) may be prepared by reacting a compound of formula (VI) wherein R is as hereinbefore defined, with a compound of formula (VII) using, for example, Friedel-Crafts acylation conditions.
- Compounds of formula (VI) may be prepared by reacting a compound of formula (VIII) with a suitable reagent or reagents and under such conditions as to substitute the group R of compound (VI) in the o -position, for example, in the case where R is nitro, by selective nitration using c.H2SO4/c.HNO3 at low temperature.
- Optional conversion of the compound of formula (I) to a corresponding salt may be effected by reaction with the appropriate acid or base.
- the "active ingredient” may be the compound of formula (I) as hereinbefore defined.
- formulations A, B and C may be prepared by wet granulation of ingredients (a) to (c), (a) to (d) and (a) to (c) respectively with a solution of povidone, followed by addition of the magnesium stearate and compression.
- formulations D and E may be prepared by direct compression of the admixed ingredients.
- the lactose used in formulation E is of the direct compression type.
- the formulation may be prepared by wet granulation of ingredients (a) to (c) with a solution of povidone, followed by addition of the magnesium stearate and compression.
- Capsules may be prepared by admixing the ingredients of Formulation D above and filling two-part hard gelatin capsules with the resulting mixture.
- Formulation B (infra) may be prepared in a similar manner.
- Capsules may be prepared by melting the Macrogel 4000 BP, dispersing the active ingredient in the melt, and filling two-part hard gelatin capsules therewith.
- Capsules may be prepared by dispersing the active ingredient in the lecithin and arachis oil and filling soft, elastic gelatin capsules with the dispersion.
- the controlled-release capsule formulation may be prepared by extruding mixed ingredients (a) to (c) using an extruder, then spheronising and drying the extrudate.
- the dried pellets are coated with ethyl cellulose (d) as a controlled-release membrane and filled into two-part hard gelatin capsules.
- Active ingredient 0.200g Sterile, pyrogend-free phosphate buffer (pH 9.0) to 10 ml
- the active ingredient is dissolved in most of the phosphate buffer at 35-40°C, then made up to volume and filtered through a sterile micropore filter into sterile 10 ml glass vials (Type 1) which are sealed with sterile closures and overseals.
- the active ingredient is dissolved in the glycofurol.
- the benzyl alcohol is then added and dissolved, and water added to 3 ml.
- the mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml glass vials (Type 1).
- the sodium benzoate is dissolved in a portion of the purified water and the sorbitol solution added.
- the active ingredient is added and dissolved.
- the resulting solution is mixed with the glycerol and then made up to the required volume with the purified water.
- Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum.
- the active ingredient is sifted through a 200 ⁇ m sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45°C, the remaining Witepsol H15 is added to the suspension which is stirred to ensure a homogenous mix.
- the entire suspension is then passed through a 250 ⁇ m stainless steel screen and, with continuous stirring, allowed to cool to 40°C. At a temperature of 38-40°C, 2.02g aliquots of the mixture are filled into suitable plastic moulds and the suppositories allowed to cool to room temperature.
- the enzyme is membrane-associated in vivo . Microsomal protein is therefore used as the source of both ACAT and cholesterol.
- the compound of the invention was tested against enzyme derived from human embryo 407 intestinal epithelial cell line.
- [14C]Oleoyl CoA was incubated with microsomal protein at 37°C, pH 7.0, in the presence of various concentrations of the test compound. After 4 minutes, the reaction was stopped by the addition of ice-cold chloroform/methanol containing a known amount of [3H]oleoyl cholesterol to compensate for the loss of any [14C] product. A known volume of the resulting lower phase, which contains lipidic material from the reaction, was dried, redissolved in hexane containing unlabelled oleoyl cholesterol (TLC marker) and run on a quantitative TLC plate (silica gel). The oleoyl cholesterol spot was visualised (iodine vapour), removed from the TLC plate and its radioactivity measured by scintillation counting.
- TLC marker unlabelled oleoyl cholesterol
- a plot of ACAT inhibitory activity vs concentration was prepared for the test compound and the corresponding IC50 determined.
- the compound of the invention was found to significantly inhibit ACAT with an IC50 for ACAT inhibition of 0.022 ⁇ M.
- the cytotoxicity of the compound of the invention was investigated in vitro by studying its effects on the metabolic competence of isolated rat liver cells. No effect on gluconeogenesis was observed at concentrations of up to 100 ⁇ M. A 15% decrease in ATP levels was observed after 90 minutes at a concentration of 100 ⁇ M.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Eye Examination Apparatus (AREA)
- Polarising Elements (AREA)
- Prostheses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT91107475T ATE102604T1 (de) | 1988-11-21 | 1991-05-08 | Diarylverbindungen als antiatherosklerotische mittel. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB888827152A GB8827152D0 (en) | 1988-11-21 | 1988-11-21 | Anti-atherosclerotic diaryl compounds |
GB8827152 | 1988-11-21 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP89312025.3 Division | 1989-11-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0450660A1 EP0450660A1 (en) | 1991-10-09 |
EP0450660B1 true EP0450660B1 (en) | 1994-03-09 |
Family
ID=10647180
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP89312025A Expired - Lifetime EP0370740B1 (en) | 1988-11-21 | 1989-11-20 | Anti-atherosclerotic diaryl compounds |
EP91107475A Expired - Lifetime EP0450660B1 (en) | 1988-11-21 | 1989-11-20 | Anti-atherosclerotic diaryl compound |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP89312025A Expired - Lifetime EP0370740B1 (en) | 1988-11-21 | 1989-11-20 | Anti-atherosclerotic diaryl compounds |
Country Status (27)
Country | Link |
---|---|
EP (2) | EP0370740B1 (el) |
JP (1) | JPH02188568A (el) |
KR (1) | KR900007790A (el) |
AT (2) | ATE78812T1 (el) |
AU (1) | AU638950B2 (el) |
CA (1) | CA2003395A1 (el) |
CZ (1) | CZ277693B6 (el) |
DD (1) | DD289263A5 (el) |
DE (2) | DE68913762T2 (el) |
DK (1) | DK581889A (el) |
ES (2) | ES2062610T3 (el) |
FI (1) | FI895520A0 (el) |
GB (1) | GB8827152D0 (el) |
GR (1) | GR3006091T3 (el) |
HU (1) | HU205342B (el) |
IE (2) | IE65411B1 (el) |
IL (1) | IL92358A (el) |
LT (1) | LTIP418A (el) |
MX (1) | MX9203417A (el) |
MY (1) | MY106247A (el) |
NO (1) | NO172233C (el) |
NZ (1) | NZ231448A (el) |
PL (1) | PL162010B1 (el) |
PT (2) | PT92354A (el) |
RU (1) | RU2036901C1 (el) |
TW (1) | TW213445B (el) |
ZA (1) | ZA898842B (el) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ229828A (en) * | 1988-08-09 | 1992-03-26 | Squibb & Sons Inc | Aryl cyanoguanidine derivatives and pharmaceutical compositions |
US5290814A (en) * | 1988-11-21 | 1994-03-01 | Burroughs Wellcome Co. | Anti-atherosclerotic diaryl compounds |
GB9020841D0 (en) * | 1990-09-25 | 1990-11-07 | Wellcome Found | Anti-atherosclerotic aryl compounds |
GB9027023D0 (en) * | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
IL100915A (en) * | 1991-02-19 | 1996-03-31 | Erba Carlo Spa | Double-transformed urea and theories, their preparation and pharmaceutical preparations containing them |
US5310748A (en) * | 1992-05-11 | 1994-05-10 | The Du Pont Merck Pharmaceutical Company | Imidazoles for the treatment of atherosclerosis |
US5364875A (en) * | 1992-05-11 | 1994-11-15 | The Du Pont Merck Pharmaceutical Company | Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis |
CA2123728A1 (en) * | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
EP0706508A1 (en) * | 1993-06-30 | 1996-04-17 | The Wellcome Foundation Limited | Anti-atherosclerotic diaryl compounds |
NZ264063A (en) * | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
US5547966A (en) * | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
US5576335A (en) * | 1994-02-01 | 1996-11-19 | Nisshin Flour Milling Co., Ltd. | Urea derivatives and their use as ACAT inhibitors |
US5491152A (en) * | 1994-03-23 | 1996-02-13 | The Du Pont Merck Pharmaceutical Company | Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis |
CA2200981A1 (en) * | 1994-10-04 | 1996-04-11 | Hisashi Takasugi | Urea derivatives and their use as acat-inhibitors |
EP0742208A1 (en) * | 1995-05-05 | 1996-11-13 | Grelan Pharmaceutical Co., Ltd. | 2-Ureido-benzamide derivatives |
US5866609A (en) * | 1996-08-09 | 1999-02-02 | Ss Pharmaceutical Co., Ltd. | Substituted vinylurea derivatives and medicine containing the same |
FR2946342B1 (fr) | 2009-06-05 | 2011-06-24 | Galderma Res & Dev | Nouveaux derives de dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
FR2946345B1 (fr) | 2009-06-05 | 2011-05-20 | Galderma Res & Dev | Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
FR2946340B1 (fr) | 2009-06-05 | 2011-06-24 | Galderma Res & Dev | Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
FR2946346B1 (fr) | 2009-06-05 | 2011-05-20 | Galderma Res & Dev | Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1382526A (en) * | 1972-08-11 | 1975-02-05 | Ici Ltd | Morpholine derivatives |
US4029786A (en) * | 1972-08-11 | 1977-06-14 | Imperial Chemical Industries Limited | Morpholine derivatives for treating depression |
ZA801680B (en) * | 1979-04-03 | 1981-03-25 | Fujisawa Pharmaceutical Co | 2-imidazoline derivatives,process for the preparation thereof and the pharmaceutical composition of the same |
US4269829A (en) * | 1979-06-18 | 1981-05-26 | Rohm And Haas Company | Method and composition for treating helminths containing O,O-dialkyl-N-(substituted phenyl)aminothiocarbonyl phosphoramidates |
US4387106A (en) * | 1982-01-26 | 1983-06-07 | American Cyanamid Company | Method of treating atherosclerosis with di(aralkyl)ureas and di(aralkyl)thioureas |
EP0130202A1 (en) * | 1982-12-30 | 1985-01-09 | Beecham Group Plc | Tetracyclic compounds |
US4603145A (en) * | 1983-05-06 | 1986-07-29 | American Cyanamid Company | Antiatherosclerotic diphenyl alkanamides |
US4716175A (en) * | 1987-02-24 | 1987-12-29 | Warner-Lambert Company | Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase |
ES2037768T3 (es) * | 1987-07-02 | 1993-07-01 | Warner-Lambert Company | Procedimiento para preparar n-(fenil(2,6-disustituido))-ureas y carbamatos inhibidores de acil-coa: colesterol acil-transferasa. |
-
1988
- 1988-11-21 GB GB888827152A patent/GB8827152D0/en active Pending
-
1989
- 1989-11-20 AU AU45363/89A patent/AU638950B2/en not_active Ceased
- 1989-11-20 IL IL9235889A patent/IL92358A/en not_active IP Right Cessation
- 1989-11-20 EP EP89312025A patent/EP0370740B1/en not_active Expired - Lifetime
- 1989-11-20 CZ CS896558A patent/CZ277693B6/cs unknown
- 1989-11-20 EP EP91107475A patent/EP0450660B1/en not_active Expired - Lifetime
- 1989-11-20 PL PL89282377A patent/PL162010B1/pl unknown
- 1989-11-20 PT PT92354A patent/PT92354A/pt not_active Application Discontinuation
- 1989-11-20 ES ES91107475T patent/ES2062610T3/es not_active Expired - Lifetime
- 1989-11-20 NO NO894616A patent/NO172233C/no unknown
- 1989-11-20 ES ES89312025T patent/ES2052028T3/es not_active Expired - Lifetime
- 1989-11-20 HU HU896019A patent/HU205342B/hu not_active IP Right Cessation
- 1989-11-20 IE IE370089A patent/IE65411B1/en not_active IP Right Cessation
- 1989-11-20 AT AT89312025T patent/ATE78812T1/de not_active IP Right Cessation
- 1989-11-20 DE DE68913762T patent/DE68913762T2/de not_active Expired - Fee Related
- 1989-11-20 CA CA002003395A patent/CA2003395A1/en not_active Abandoned
- 1989-11-20 FI FI895520A patent/FI895520A0/fi not_active Application Discontinuation
- 1989-11-20 DD DD89334709A patent/DD289263A5/de not_active IP Right Cessation
- 1989-11-20 NZ NZ231448A patent/NZ231448A/en unknown
- 1989-11-20 KR KR1019890016909A patent/KR900007790A/ko not_active Application Discontinuation
- 1989-11-20 DE DE8989312025T patent/DE68902301T2/de not_active Expired - Fee Related
- 1989-11-20 IE IE940341A patent/IE940341L/xx unknown
- 1989-11-20 DK DK581889A patent/DK581889A/da not_active Application Discontinuation
- 1989-11-20 ZA ZA898842A patent/ZA898842B/xx unknown
- 1989-11-20 MY MYPI89001613A patent/MY106247A/en unknown
- 1989-11-20 RU SU894742525A patent/RU2036901C1/ru active
- 1989-11-20 JP JP1301811A patent/JPH02188568A/ja active Pending
- 1989-11-21 TW TW078109041A patent/TW213445B/zh active
-
1991
- 1991-05-08 AT AT91107475T patent/ATE102604T1/de not_active IP Right Cessation
-
1992
- 1992-06-25 MX MX9203417A patent/MX9203417A/es unknown
- 1992-10-27 GR GR920402420T patent/GR3006091T3/el unknown
-
1993
- 1993-03-15 LT LTIP418A patent/LTIP418A/xx unknown
-
1995
- 1995-06-21 PT PT101725A patent/PT101725B/pt not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0450660B1 (en) | Anti-atherosclerotic diaryl compound | |
US5696138A (en) | Urea derivatives and their use | |
EP2560949B1 (en) | Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2 | |
US5384330A (en) | Pharmaceutically active 1,2,4-triamino-benzene derivatives, processes for their preparation and pharmaceutical compositions containing them | |
JP2575183B2 (ja) | 抗高脂血性および抗アテローム性動脈硬化性の尿素およびカルバメート化合物 | |
US5290814A (en) | Anti-atherosclerotic diaryl compounds | |
US5063247A (en) | Diphenylurea derivatives | |
HU184959B (en) | Process for producing new amino-ethanel derivatives | |
EP0297610B1 (en) | N-[(2,6-disubstituted)phenyl]-urea and carbamate inhibitors of acyl-CoA:cholesterol acyl-transferase | |
JP2572115B2 (ja) | 抗増殖剤として有用な5−アミノ又は置換アミノ−1,2,3− トリアゾール類 | |
AU620966B2 (en) | Novel n-(substituted aryl)-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents | |
CS209856B2 (en) | Method of making the new derivatives of the aminoacids | |
CA1263964A (en) | Substituted anilides of oleic, linoleic, or linolenic acid as inhibitors of acyl-coa:cholesterol acyltransferase | |
EP0240263B1 (en) | Indenopyrimidine derivatives | |
AU626308B2 (en) | (((Cycloalkylthiazolyl)ethenyl)phenylamino)-oxoalkanoic acid derivatives | |
JPH06502415A (ja) | オキシスルホニルカルバメート | |
RU2090555C1 (ru) | Производные мочевины, способ получения производных мочевины, фармацевтическая композиция, обладающая ингибирующей активностью в отношении coa : холестерин-ацилтрансферазы (асат) | |
US5053426A (en) | Simplified thioester and isostere analogs of oleoyl coenzyme a as hypocholesterolemic agents | |
NZ207272A (en) | Benzamide derivatives and pharmaceutical compositions | |
EP0777471B1 (en) | Inhibition of leukotriene biosynthesis with urea derivatives | |
AU747173B2 (en) | Novel urethanes, thio and dithio analogues, the salts thereof, medicaments containing said compounds, use and method for the production thereof | |
IE912849A1 (en) | Benzanilide derivatives | |
US4973734A (en) | Carbaphens: aprophen analogs that are binary antidotes for organophosphate poisoning | |
JPH1017530A (ja) | アニリン誘導体および細胞傷害防御剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19910508 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 370740 Country of ref document: EP |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19921003 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
ITF | It: translation for a ep patent filed |
Owner name: BARZANO' E ZANARDO ROMA S.P.A. |
|
AC | Divisional application: reference to earlier application |
Ref document number: 370740 Country of ref document: EP |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 102604 Country of ref document: AT Date of ref document: 19940315 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 68913762 Country of ref document: DE Date of ref document: 19940414 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3011600 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2062610 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
EAL | Se: european patent in force in sweden |
Ref document number: 91107475.5 |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19951109 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19951113 Year of fee payment: 7 Ref country code: AT Payment date: 19951113 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19951116 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 19951128 Year of fee payment: 7 Ref country code: ES Payment date: 19951128 Year of fee payment: 7 Ref country code: DE Payment date: 19951128 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19951129 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19951208 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19960101 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19960109 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19961120 Ref country code: GB Effective date: 19961120 Ref country code: AT Effective date: 19961120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19961121 Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 19961121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19961130 Ref country code: CH Effective date: 19961130 Ref country code: BE Effective date: 19961130 |
|
BERE | Be: lapsed |
Owner name: THE WELLCOME FOUNDATION LTD Effective date: 19961130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 19970531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19970601 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: MM2A Free format text: 3011600 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19961120 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19970731 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19970601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19970801 |
|
EUG | Se: european patent has lapsed |
Ref document number: 91107475.5 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20010301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20051120 |